Leonard Zehr, Author at BioTuesdays

This Week's Feature

ReShape Lifesciences forging weight loss and metabolic health solutions

With an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease, ReShape Lifesciences (NASDAQ:RSLS) is reshaping patients minds, bodies and lives.

September 21, 2021

Features

UNITY Biotechnology developing therapeutics to slow, halt or reverse diseases of aging

UNITY Biotechnology’s (NASDAQ:UBX) current focus is on developing medicines to selectively eliminate or modulate senescent cells and to provide transformative benefit in age-related ophthalmologic and neurologic...

September 14, 2021

Features

RNA Disease Diagnostics to disrupt and democratize molecular testing with POC and home-use focus

RNA Disease Diagnostics (RNADD) is positioning its Antisense Molecular Diagnostic Platform to disrupt diagnostic testing with a rapid, point-of-care (POC) molecular COVID-19 test at high-traffic locations, such as...

September 7, 2021

Features

Bombi Biomics fighting superbugs with amphibian-derived anti-microbial peptides

Closely-held Bombi Biomics of the Netherlands has developed a technology known as Bombilysin with the potential to kill bacteria from the outside shell in contrast to conventional antibiotics that typically are intended...

August 31, 2021

Developments

iBio acquires exclusive rights to develop anti-CD25 antibody RTX-003 from RubrYc

iBio (NYSEA:IBIO) bolstered its immuno-oncology pipeline with the acquisition of exclusive rights to develop and commercialize the anti-CD25 monoclonal antibody, RTX-003, from RubrYc. The partnership also includes an...

August 25, 2021

Features

Anebulo Pharma addressing cannabinoid intoxication as legalization grows

Anebulo Pharmaceuticals (NASDAQ:ANEB) is developing a novel antidote for cannabinoid intoxication and, longer term, other indications related to abuse and addiction.

August 24, 2021

Features

Lucid Psycheceuticals focusing on Total Brain Health

Lucid Psycheceuticals’ next generation approach to total brain health is targeting the interface between mental health and neurodegenerative disorders with therapeutic products inspired by psychedelics and new chemical...

August 17, 2021

Features

Taming cytokine storm syndrome with Jim Joyce of Sigyn Therapeutics

As a co-founder, chairman and CEO of Sigyn Therapeutics (pronounced Sig-en) (OTCMarkets:SIGY), a medical device company developing a blood purification system to treat life-threatening inflammatory conditions, including...

August 10, 2021

Features

Altamira in strategic repositioning to develop RNA therapeutics

Altamira Therapeutics (NASDAQ:CYTO) is using its recent acquisition of closely-held Trasir Therapeutics as a steppingstone for a strategic repositioning to focus on development of RNA therapeutics, while in the medium...

August 3, 2021

Features

LENZ Therapeutics readies pivotal trial of aceclidine to treat presbyopia

With a new, experienced management team and a $47-million series A financing in place, closely-held LENZ Therapeutics is gearing up for a pivotal trial of its aceclidine once-daily eye drop to treat presbyopia, the...

July 27, 2021

Author - Leonard Zehr

ReShape Lifesciences forging weight loss and metabolic health solutions

UNITY Biotechnology developing therapeutics to slow, halt or reverse diseases of aging

RNA Disease Diagnostics to disrupt and democratize molecular testing with POC and home-use focus

Bombi Biomics fighting superbugs with amphibian-derived anti-microbial peptides

iBio acquires exclusive rights to develop anti-CD25 antibody RTX-003 from RubrYc

Anebulo Pharma addressing cannabinoid intoxication as legalization grows

Lucid Psycheceuticals focusing on Total Brain Health

Taming cytokine storm syndrome with Jim Joyce of Sigyn Therapeutics

Altamira in strategic repositioning to develop RNA therapeutics

LENZ Therapeutics readies pivotal trial of aceclidine to treat presbyopia

General

More